Dr. Bendell on the Future of Regorafenib for Patients With CRC
Johanna C. Bendell, MD
Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses the future of regorafenib (Stivarga) for patients with colorectal cancer (CRC).
Further studies need to be done to determine the best dosage for regorafenib because most patients cannot tolerate the current dose, says Bendell.
A current trial conducted by researchers out of Mayo Clinic is comparing the full dosage to a lower dosage to see if tolerability will translate into increased progression-free survival, explains Bendell.